http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 27 May 2026 08:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Vistagen+to+Participate+in+Jefferies+2026+Global+Healthcare+Conference/26554058.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vistagen.com&amp;esheet=54542226&amp;newsitemid=20260527302319&amp;lan=en-US&amp;anchor=Vistagen&amp;index=1&amp;md5=fc41860b3778784660595eea20f36f91" shape="rect">Vistagen</a>, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the Jefferies 2026 Global Healthcare conference being held June 2-4, 2026, in New York City. </p><p> The Company will host one-on-one meetings with institutional investors during the conference. Investors interested in scheduling a meeting with Vistagen are encouraged to contact their Jefferies representative. </p><p> <b>About Vistagen</b> </p><p> Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain http://www.streetinsider.com/Press+Releases/Vistagen+to+Participate+in+Jefferies+2026+Global+Healthcare+Conference/26554058.html Wed, 27 May 2026 08:30:00 -0400 O.07328903 VTGN http://www.streetinsider.com/Press+Releases/Vistagen+to+Participate+in+Jefferies+2026+Global+Healthcare+Conference/26554058.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vistagen.com&amp;esheet=54542226&amp;newsitemid=20260527302319&amp;lan=en-US&amp;anchor=Vistagen&amp;index=1&amp;md5=fc41860b3778784660595eea20f36f91" shape="rect">Vistagen</a>, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the Jefferies 2026 Global Healthcare conference being held June 2-4, 2026, in New York City. </p><p> The Company will host one-on-one meetings with institutional investors during the conference. Investors interested in scheduling a meeting with Vistagen are encouraged to contact their Jefferies representative. </p><p> <b>About Vistagen</b> </p><p> Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain http://www.streetinsider.com/Press+Releases/Vistagen+to+Participate+in+Jefferies+2026+Global+Healthcare+Conference/26554058.html Wed, 27 May 2026 08:30:00 -0400 O.07328903 VTGN http://www.streetinsider.com/Business+Wire/Vistagen+to+Participate+in+Jefferies+2026+Global+Healthcare+Conference/26554058.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vistagen.com&amp;esheet=54542226&amp;newsitemid=20260527302319&amp;lan=en-US&amp;anchor=Vistagen&amp;index=1&amp;md5=fc41860b3778784660595eea20f36f91" shape="rect">Vistagen</a>, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the Jefferies 2026 Global Healthcare conference being held June 2-4, 2026, in New York City. </p><p> The Company will host one-on-one meetings with institutional investors during the conference. Investors interested in scheduling a meeting with Vistagen are encouraged to contact their Jefferies representative. </p><p> <b>About Vistagen</b> </p><p> Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain http://www.streetinsider.com/Business+Wire/Vistagen+to+Participate+in+Jefferies+2026+Global+Healthcare+Conference/26554058.html Wed, 27 May 2026 08:30:00 -0400 O.07328903 VTGN http://www.streetinsider.com/Business+Wire/Vistagen+to+Participate+in+Jefferies+2026+Global+Healthcare+Conference/26554058.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vistagen.com&amp;esheet=54542226&amp;newsitemid=20260527302319&amp;lan=en-US&amp;anchor=Vistagen&amp;index=1&amp;md5=fc41860b3778784660595eea20f36f91" shape="rect">Vistagen</a>, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the Jefferies 2026 Global Healthcare conference being held June 2-4, 2026, in New York City. </p><p> The Company will host one-on-one meetings with institutional investors during the conference. Investors interested in scheduling a meeting with Vistagen are encouraged to contact their Jefferies representative. </p><p> <b>About Vistagen</b> </p><p> Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain http://www.streetinsider.com/Business+Wire/Vistagen+to+Participate+in+Jefferies+2026+Global+Healthcare+Conference/26554058.html Wed, 27 May 2026 08:30:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vistagen+Therapeutics%2C++++For%3A+May+18++Filed+by%3A+Angelov+Angel+S/26522195.html si-local-file:///var/storage/secattach/20260519/26522195.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vistagen+Therapeutics%2C++++For%3A+May+18++Filed+by%3A+Angelov+Angel+S/26522195.html Tue, 19 May 2026 16:52:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vistagen+Therapeutics%2C++++For%3A+May+18++Filed+by%3A+Angelov+Angel+S/26522195.html si-local-file:///var/storage/secattach/20260519/26522195.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vistagen+Therapeutics%2C++++For%3A+May+18++Filed+by%3A+Angelov+Angel+S/26522195.html Tue, 19 May 2026 16:52:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+May+18++Filed+by%3A+Angelov+Angel+S/26522204.html si-local-file:///var/storage/secattach/20260519/26522204.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+May+18++Filed+by%3A+Angelov+Angel+S/26522204.html Tue, 19 May 2026 16:52:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+May+18++Filed+by%3A+Angelov+Angel+S/26522204.html si-local-file:///var/storage/secattach/20260519/26522204.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vistagen+Therapeutics%2C++++For%3A+May+18++Filed+by%3A+Angelov+Angel+S/26522204.html Tue, 19 May 2026 16:52:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+May+18/26521688.html si-local-file:///var/storage/secattach/20260519/26521688.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+May+18/26521688.html Tue, 19 May 2026 16:30:00 -0400 O.07328903 VTGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+May+18/26521688.html si-local-file:///var/storage/secattach/20260519/26521688.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+May+18/26521688.html Tue, 19 May 2026 16:30:00 -0400 O.07328903 VTGN http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html <p>Vistagen (NASDAQ: VTGN) appointed Angel S. Angelov as chief medical officer, effective May 18, 2026, according to a company statement.</p> <p>Angelov brings two decades of experience in clinical development and medical affairs. He most recently served as chief medical officer at Theranica, a neuromodulation therapeutics company. His previous roles include managing director at ANG Holding, vice president and head of medical affairs at Karuna Therapeutics, and vice president and clinical leader for the VMAT-2 franchise at Neurocrine Biosciences.</p> <p>Angelov has also held positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, along with faculty positions at Thomas Jefferson University and Temple University. He http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html Tue, 19 May 2026 08:30:27 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html <p>Vistagen (NASDAQ: VTGN) appointed Angel S. Angelov as chief medical officer, effective May 18, 2026, according to a company statement.</p> <p>Angelov brings two decades of experience in clinical development and medical affairs. He most recently served as chief medical officer at Theranica, a neuromodulation therapeutics company. His previous roles include managing director at ANG Holding, vice president and head of medical affairs at Karuna Therapeutics, and vice president and clinical leader for the VMAT-2 franchise at Neurocrine Biosciences.</p> <p>Angelov has also held positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, along with faculty positions at Thomas Jefferson University and Temple University. He http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html Tue, 19 May 2026 08:30:27 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html <p>Vistagen (NASDAQ: VTGN) appointed Angel S. Angelov as chief medical officer, effective May 18, 2026, according to a company statement.</p> <p>Angelov brings two decades of experience in clinical development and medical affairs. He most recently served as chief medical officer at Theranica, a neuromodulation therapeutics company. His previous roles include managing director at ANG Holding, vice president and head of medical affairs at Karuna Therapeutics, and vice president and clinical leader for the VMAT-2 franchise at Neurocrine Biosciences.</p> <p>Angelov has also held positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, along with faculty positions at Thomas Jefferson University and Temple University. He http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html Tue, 19 May 2026 08:30:27 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html <p>Vistagen (NASDAQ: VTGN) appointed Angel S. Angelov as chief medical officer, effective May 18, 2026, according to a company statement.</p> <p>Angelov brings two decades of experience in clinical development and medical affairs. He most recently served as chief medical officer at Theranica, a neuromodulation therapeutics company. His previous roles include managing director at ANG Holding, vice president and head of medical affairs at Karuna Therapeutics, and vice president and clinical leader for the VMAT-2 franchise at Neurocrine Biosciences.</p> <p>Angelov has also held positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, along with faculty positions at Thomas Jefferson University and Temple University. He http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html Tue, 19 May 2026 08:30:27 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html <p>Vistagen (NASDAQ: VTGN) appointed Angel S. Angelov as chief medical officer, effective May 18, 2026, according to a company statement.</p> <p>Angelov brings two decades of experience in clinical development and medical affairs. He most recently served as chief medical officer at Theranica, a neuromodulation therapeutics company. His previous roles include managing director at ANG Holding, vice president and head of medical affairs at Karuna Therapeutics, and vice president and clinical leader for the VMAT-2 franchise at Neurocrine Biosciences.</p> <p>Angelov has also held positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, along with faculty positions at Thomas Jefferson University and Temple University. He http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html Tue, 19 May 2026 08:30:27 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html <p>Vistagen (NASDAQ: VTGN) appointed Angel S. Angelov as chief medical officer, effective May 18, 2026, according to a company statement.</p> <p>Angelov brings two decades of experience in clinical development and medical affairs. He most recently served as chief medical officer at Theranica, a neuromodulation therapeutics company. His previous roles include managing director at ANG Holding, vice president and head of medical affairs at Karuna Therapeutics, and vice president and clinical leader for the VMAT-2 franchise at Neurocrine Biosciences.</p> <p>Angelov has also held positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, along with faculty positions at Thomas Jefferson University and Temple University. He http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html Tue, 19 May 2026 08:30:27 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html <p>Vistagen (NASDAQ: VTGN) appointed Angel S. Angelov as chief medical officer, effective May 18, 2026, according to a company statement.</p> <p>Angelov brings two decades of experience in clinical development and medical affairs. He most recently served as chief medical officer at Theranica, a neuromodulation therapeutics company. His previous roles include managing director at ANG Holding, vice president and head of medical affairs at Karuna Therapeutics, and vice president and clinical leader for the VMAT-2 franchise at Neurocrine Biosciences.</p> <p>Angelov has also held positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, along with faculty positions at Thomas Jefferson University and Temple University. He http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html Tue, 19 May 2026 08:30:27 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html <p>Vistagen (NASDAQ: VTGN) appointed Angel S. Angelov as chief medical officer, effective May 18, 2026, according to a company statement.</p> <p>Angelov brings two decades of experience in clinical development and medical affairs. He most recently served as chief medical officer at Theranica, a neuromodulation therapeutics company. His previous roles include managing director at ANG Holding, vice president and head of medical affairs at Karuna Therapeutics, and vice president and clinical leader for the VMAT-2 franchise at Neurocrine Biosciences.</p> <p>Angelov has also held positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, along with faculty positions at Thomas Jefferson University and Temple University. He http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html Tue, 19 May 2026 08:30:27 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html <p>Vistagen (NASDAQ: VTGN) appointed Angel S. Angelov as chief medical officer, effective May 18, 2026, according to a company statement.</p> <p>Angelov brings two decades of experience in clinical development and medical affairs. He most recently served as chief medical officer at Theranica, a neuromodulation therapeutics company. His previous roles include managing director at ANG Holding, vice president and head of medical affairs at Karuna Therapeutics, and vice president and clinical leader for the VMAT-2 franchise at Neurocrine Biosciences.</p> <p>Angelov has also held positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, along with faculty positions at Thomas Jefferson University and Temple University. He http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html Tue, 19 May 2026 08:30:27 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html <p>Vistagen (NASDAQ: VTGN) appointed Angel S. Angelov as chief medical officer, effective May 18, 2026, according to a company statement.</p> <p>Angelov brings two decades of experience in clinical development and medical affairs. He most recently served as chief medical officer at Theranica, a neuromodulation therapeutics company. His previous roles include managing director at ANG Holding, vice president and head of medical affairs at Karuna Therapeutics, and vice president and clinical leader for the VMAT-2 franchise at Neurocrine Biosciences.</p> <p>Angelov has also held positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, along with faculty positions at Thomas Jefferson University and Temple University. He http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html Tue, 19 May 2026 08:30:27 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html <p>Vistagen (NASDAQ: VTGN) appointed Angel S. Angelov as chief medical officer, effective May 18, 2026, according to a company statement.</p> <p>Angelov brings two decades of experience in clinical development and medical affairs. He most recently served as chief medical officer at Theranica, a neuromodulation therapeutics company. His previous roles include managing director at ANG Holding, vice president and head of medical affairs at Karuna Therapeutics, and vice president and clinical leader for the VMAT-2 franchise at Neurocrine Biosciences.</p> <p>Angelov has also held positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, along with faculty positions at Thomas Jefferson University and Temple University. He http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html Tue, 19 May 2026 08:30:27 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html <p>Vistagen (NASDAQ: VTGN) appointed Angel S. Angelov as chief medical officer, effective May 18, 2026, according to a company statement.</p> <p>Angelov brings two decades of experience in clinical development and medical affairs. He most recently served as chief medical officer at Theranica, a neuromodulation therapeutics company. His previous roles include managing director at ANG Holding, vice president and head of medical affairs at Karuna Therapeutics, and vice president and clinical leader for the VMAT-2 franchise at Neurocrine Biosciences.</p> <p>Angelov has also held positions at CollaGenex, Indivior, Novartis, NuPathe, and Teva, along with faculty positions at Thomas Jefferson University and Temple University. He http://www.streetinsider.com/Management+Changes/Vistagen+names+Angel+Angelov+as+chief+medical+officer/26517935.html Tue, 19 May 2026 08:30:27 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Press+Releases/Vistagen+Appoints+Angel+S.+Angelov%2C+MD%2C+MBA%2C+as+Chief+Medical+Officer/26517899.html <p class="bwalignc"> <i>Dr. Angelov brings extensive industry experience across multiple therapeutic areas</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vistagen.com%2F&amp;esheet=54538171&amp;newsitemid=20260519798012&amp;lan=en-US&amp;anchor=Vistagen&amp;index=1&amp;md5=87e9550589bb63f5760b4401e0a40bdf" shape="rect">Vistagen</a> (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. </p><p> "We are pleased to welcome Dr. Angelov to the Vistagen team,” said President and Chief Executive Officer of Vistagen, Shawn Singh. “His two decades of leadership across clinical development and medical affairs, including roles http://www.streetinsider.com/Press+Releases/Vistagen+Appoints+Angel+S.+Angelov%2C+MD%2C+MBA%2C+as+Chief+Medical+Officer/26517899.html Tue, 19 May 2026 08:30:00 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Press+Releases/Vistagen+Appoints+Angel+S.+Angelov%2C+MD%2C+MBA%2C+as+Chief+Medical+Officer/26517899.html <p class="bwalignc"> <i>Dr. Angelov brings extensive industry experience across multiple therapeutic areas</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vistagen.com%2F&amp;esheet=54538171&amp;newsitemid=20260519798012&amp;lan=en-US&amp;anchor=Vistagen&amp;index=1&amp;md5=87e9550589bb63f5760b4401e0a40bdf" shape="rect">Vistagen</a> (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. </p><p> "We are pleased to welcome Dr. Angelov to the Vistagen team,” said President and Chief Executive Officer of Vistagen, Shawn Singh. “His two decades of leadership across clinical development and medical affairs, including roles http://www.streetinsider.com/Press+Releases/Vistagen+Appoints+Angel+S.+Angelov%2C+MD%2C+MBA%2C+as+Chief+Medical+Officer/26517899.html Tue, 19 May 2026 08:30:00 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN http://www.streetinsider.com/Press+Releases/Vistagen+Appoints+Angel+S.+Angelov%2C+MD%2C+MBA%2C+as+Chief+Medical+Officer/26517899.html <p class="bwalignc"> <i>Dr. Angelov brings extensive industry experience across multiple therapeutic areas</i> </p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vistagen.com%2F&amp;esheet=54538171&amp;newsitemid=20260519798012&amp;lan=en-US&amp;anchor=Vistagen&amp;index=1&amp;md5=87e9550589bb63f5760b4401e0a40bdf" shape="rect">Vistagen</a> (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. </p><p> "We are pleased to welcome Dr. Angelov to the Vistagen team,” said President and Chief Executive Officer of Vistagen, Shawn Singh. “His two decades of leadership across clinical development and medical affairs, including roles http://www.streetinsider.com/Press+Releases/Vistagen+Appoints+Angel+S.+Angelov%2C+MD%2C+MBA%2C+as+Chief+Medical+Officer/26517899.html Tue, 19 May 2026 08:30:00 -0400 A.00437200 A.03607790 A.14343089 A.27521928 A.50114120 O.02663065 O.07328903 O.20142229 O.20147506 O.41343427 O.48111428 VTGN